Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 15/20 | 0.39 |
| ▸ | CTSL | P07711 | 8/20 | 0.38 |
| ▸ | CTSS | P25774 | 7/20 | 0.38 |
| ▸ | CTSB | P07858 | 3/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042987 | 0.83 | ADAM17 (0.38) | AVPR1ACTSKCTSLCTSSCTSB | |
| SCHEMBL3046320 | 0.75 | GRIN2B (0.42) | AVPR1ACTSKCTSLCTSS | |
| SCHEMBL4604125 | 0.75 | GRIN2B (0.42) | AVPR1ACTSKCTSLCTSS | |
| SCHEMBL19627463 | 0.72 | ALDH1A1 (0.36) | — | |
| SCHEMBL17712401 | 0.72 | ALDH1A1 (0.36) | — | |
| SCHEMBL19627475 | 0.72 | ALDH1A1 (0.36) | — | |
| SCHEMBL19614443 | 0.67 | KMT2A (0.36) | — | |
| SCHEMBL19614445 | 0.67 | KMT2A (0.36) | — | |
| SCHEMBL19614440 | 0.67 | KMT2A (0.36) | — | |
| SCHEMBL3054791 | 0.67 | NTSR1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | AVPR1A 3028/4885CTSK 3079/4885CTSL 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.